Zobrazeno 1 - 10
of 61
pro vyhledávání: ''
Publikováno v:
International Journal of Gynecologic Cancer. 31:1165-1174
The incidence and mortality rates from endometrial cancer continue to increase worldwide, while rates in most other cancers have either plateaued or declined considerably. Uterine serous carcinoma represents a fraction of all endometrial malignancies
Publikováno v:
International Journal of Gynecologic Cancer. 31:824-828
ObjectiveIn this study we investigated response rates of bevacizumab in addition to weekly paclitaxel and carboplatin in neoadjuvant setting in cervical cancer stage IB–IIB.MethodsIn this retrospective study we included patients with FIGO 2018 stag
Publikováno v:
International Journal of Gynecologic Cancer. 30:1576-1582
IntroductionWe aimed to evaluate poly (ADP-ribose) polymerase (PARP) inhibitor (PARPi) regimens in BRCA-mutated ovarian cancer for patients responsive to front-line platinum (bevacizumab and olaparib, veliparib and chemotherapy, olaparib) or platinum
Autor:
Antonio Casado, Helen Hatcher, Manon Huizing, Dan Stark, Isabelle Ray-Coquard, Nick Reed, Sarah Pratap, Barbara Hermes, Beatrice Seddon, Nicolas Isambert, Lars H. Lindner, Claudia Valverde, Paolo G. Casali, Anjana Anand, Robin L. Jones, Corneel Coens, Anne Floquet, Annekke Westermann, Emmanuelle Bompas
Publikováno v:
International journal of gynecological cancer, 30(10), 1633-1637. Wolters Kluwer Health
International journal of gynecological cancer
International journal of gynecological cancer
Funder: European Organisation for Research and Treatment of Cancer; FundRef: http://dx.doi.org/10.13039/501100004897
Funder: Ligue Nationale de Lutte contre le Cancer (France)
BACKGROUND: Uterine sarcomas are a group of rare tumors that inc
Funder: Ligue Nationale de Lutte contre le Cancer (France)
BACKGROUND: Uterine sarcomas are a group of rare tumors that inc
Autor:
Clare Green, Gianfilippo Bertelli, Marcia Hall, Chit Cheng Yeoh, Steve Chan, Timothy J. Perren, Louise Li, Agnes Ograbek, Rachel Jones, Jurjees Hasan
Publikováno v:
International Journal of Gynecologic Cancer. 30:213-220
ObjectiveTwo randomized phase III trials demonstrated the efficacy and safety of combining bevacizumab with front-line carboplatin/paclitaxel for advanced ovarian cancer. The OSCAR (NCT01863693) study assessed the impact of front-line bevacizumab-con
Publikováno v:
International Journal of Gynecologic Cancer. 29:787-791
ObjectiveTo analyze the clinical characteristics, diagnosis, and treatment of ovarian juvenile granulosa cell tumor.MethodsThe clinical and pathological data of six patients with ovarian juvenile granulosa cell tumor was collected.ResultsThe mean age
Autor:
Sandro Pignata, Kathleen N. Moore
Publikováno v:
International Journal of Gynecologic Cancer. 29:430-433
BackgroundThere is mounting pre-clinical and clinical evidence that combinations of immunotherapy, specifically programed cell death-1 (PD-1) inhibition, with chemotherapy and anti-angiogenesis agents, such as bevacizumab, result in markedly improved
Autor:
Elisa Tripodi, Stefano Lepori, Giuseppa Maltese, Gennaro Cormio, Daniela Rubino, Giorgio Valabrega, Ilaria Sabatucci, Domenica Lorusso, Ugo De Giorgi
Publikováno v:
International Journal of Gynecologic Cancer. 29:153-157
BackgroundPegylated liposomal doxorubicin (PLD) is an active and well-tolerable treatment in ovarian cancer relapse, either alone or in combination with other drugs. No data are available on the possibility to rechallenge PLD treatment in long surviv
Publikováno v:
International Journal of Gynecologic Cancer. 29:42-47
IntroductionStandard treatment for locally advanced cervical cancer (LACC) includes concomitant chemoradiotherapy (CRT) that typically controls localized disease. However, most patients develop distant metastasis, ultimately leading to death.Objectiv
Publikováno v:
International Journal of Gynecologic Cancer. 28:713-720
ObjectiveThis study aimed to investigate the role of neoadjuvant bleomycin, etoposide, and cisplatin (BEP) regimen in patients with extensively advanced yolk sac tumors (YSTs).MethodsBetween July 1982 and December 2015, a total of 58 patients with YS